US Asthma COPD Drugs Market

ID: MRFR/Pharma/14712-HCR
100 Pages
Satyendra Maurya
Last Updated: April 06, 2026
US Asthma COPD Drugs Market Research Report: Size, Share, Trend Analysis By Drug Class (Bronchodilators, Corticosteroids, Combination Drugs, Leukotriene Modifiers), By Route of Administration (Inhalation, Oral, Injection, Nasal), By Applications (Asthma, Chronic Obstructive Pulmonary Disease, Allergic Rhinitis, Pulmonary Hypertension) and By Patient Group (Adult, Pediatric, Geriatric) - Growth Outlook & Industry Forecast 2025 To 2035
US Asthma COPD Drugs Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)3.19%
2024 Market Size$ 8.5 Billion
2025 Market Size$ 8.77 Billion
2035 Market Size$ 12 Billion
Key Players
GlaxoSmithKline
Boehringer Ingelheim
AstraZeneca
Novartis
Teva Pharmaceutical Industries
Merck & Co.
Trends
  • Rise of Biologics
  • Focus on Digital Health Solutions
  • Emphasis on Preventive Care
Opportunities
  • Rising Healthcare Expenditure
  • Advancements in Drug Development
  • Growing Awareness and Education Initiatives
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Construction, BY Drug Class (USD Billion)
      1. 4.1.1 Bronchodilators
      2. 4.1.2 Corticosteroids
      3. 4.1.3 Combination Drugs
      4. 4.1.4 Leukotriene Modifiers
    2. 4.2 Construction, BY Route of Administration (USD Billion)
      1. 4.2.1 Inhalation
      2. 4.2.2 Oral
      3. 4.2.3 Injection
      4. 4.2.4 Nasal
    3. 4.3 Construction, BY Application (USD Billion)
      1. 4.3.1 Asthma
      2. 4.3.2 Chronic Obstructive Pulmonary Disease
      3. 4.3.3 Allergic Rhinitis
      4. 4.3.4 Pulmonary Hypertension
    4. 4.4 Construction, BY Patient Group (USD Billion)
      1. 4.4.1 Adult
      2. 4.4.2 Pediatric
      3. 4.4.3 Geriatric
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Construction
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 GlaxoSmithKline (GB)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Boehringer Ingelheim (DE)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 AstraZeneca (GB)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Novartis (CH)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Teva Pharmaceutical Industries (IL)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Merck & Co. (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Sanofi (FR)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Roche (CH)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Mylan (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY DRUG CLASS
    3. 6.3 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    4. 6.4 US MARKET ANALYSIS BY APPLICATION
    5. 6.5 US MARKET ANALYSIS BY PATIENT GROUP
    6. 6.6 KEY BUYING CRITERIA OF CONSTRUCTION
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF CONSTRUCTION
    9. 6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
    11. 6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION
    12. 6.12 CONSTRUCTION, BY DRUG CLASS, 2024 (% SHARE)
    13. 6.13 CONSTRUCTION, BY DRUG CLASS, 2024 TO 2035 (USD Billion)
    14. 6.14 CONSTRUCTION, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
    15. 6.15 CONSTRUCTION, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
    16. 6.16 CONSTRUCTION, BY APPLICATION, 2024 (% SHARE)
    17. 6.17 CONSTRUCTION, BY APPLICATION, 2024 TO 2035 (USD Billion)
    18. 6.18 CONSTRUCTION, BY PATIENT GROUP, 2024 (% SHARE)
    19. 6.19 CONSTRUCTION, BY PATIENT GROUP, 2024 TO 2035 (USD Billion)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY DRUG CLASS, 2025-2035 (USD Billion)
      2. 7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      3. 7.2.3 BY APPLICATION, 2025-2035 (USD Billion)
      4. 7.2.4 BY PATIENT GROUP, 2025-2035 (USD Billion)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Asthma COPD Drugs Market Segmentation

US Asthma COPD Drugs Market By Drug Class (USD Billion, 2025-2035)

  • Bronchodilators
  • Corticosteroids
  • Combination Drugs
  • Leukotriene Modifiers

US Asthma COPD Drugs Market By Route of Administration (USD Billion, 2025-2035)

  • Inhalation
  • Oral
  • Injection
  • Nasal

US Asthma COPD Drugs Market By Application (USD Billion, 2025-2035)

  • Asthma
  • Chronic Obstructive Pulmonary Disease
  • Allergic Rhinitis
  • Pulmonary Hypertension

US Asthma COPD Drugs Market By Patient Group (USD Billion, 2025-2035)

  • Adult
  • Pediatric
  • Geriatric

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.